PhRMA Calls on USPTO to Reconsider Patent Eligibility

PhRMA is urging the USPTO to reevaluate patent eligibility for prescription drugs to provide the drug industry a better framework for interpreting regulations and recent case law.
Source: Drug Industry Daily